NEW YORK (TheStreet) --Horizon Pharma (HZNP - Get Report) shares are falling 2.6% to $27.75 in after-hours trading on Monday after the pharmaceutical company announced anunderwrittenpublic share offering. The company announced that it is offering to sell 12 million shares with the underwriters of the offering expected to be granted an additional 30 days to purchase an additional 15% ofthe ordinary shares in the public offering.Citigroup (C), Jefferies, Cowen (COWN) and Morgan Stanley (MS) are acting as joint book-running managers. On Friday Horizon announced that itsACTIMMUNE treatment fora degenerative neuro-muscular disorder known asFriedreich's ataxia (FA) received fast track designation from the FDA. Shares spiked 4% following the announcement. "We commend the FDA for granting Fast Track designation for ACTIMMUNE in Friedreich's ataxia to potentially help treat patients suffering from this debilitating disorder, for which there are no FDA approved treatments available. We look forward to continuing our ongoing clinical development program as we evaluate ACTIMMUNE in this patient population,"said CEO Timothy P. Walbert. TheStreet Ratings team rates HORIZON PHARMA PLC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation: "We rate HORIZON PHARMA PLC (HZNP) a SELL. This is driven … Continue reading →

Stem Cell Therapy Market worth $330 Million in 2020 This report studies the global stem cell therapy market over the forecast period of 2015 to 2020.The market is poised to grow at a CAGR of 39.5% from 2015 to 2020, to reach $330million by 2020. By: Healthcare Market Research … Continue reading →

New research published online in Blood, the Journal of the American Society of Hematology (ASH), reports that children with "bubble boy disease" who undergo gene therapy have fewer infections and hospitalizations than those receiving stem cells from a partially matched donor. The research is the first to compare outcomes among children with the rare immune disorder -- also known as X-linked severe combined immunodeficiency (SCID-X1) -- receiving the two therapeutic approaches. Children with SCID-X1 are born with a genetic defect that prevents them from developing a normal immune system. Because they are prone to life-threatening infections, infants with SCID-X1 must be kept in a sterile, protective bubble and require extensive treatment for survival beyond infancy. Infants with SCID are most likely to survive if they receive a stem cell transplant from a fully matched donor -- typically a sibling -- a procedure that replaces an infant's diseased stem cells with healthy donor cells. Following a successful fully matched transplant, infants with SCID-X1 are able to produce their own immune cells for the first time. In the absence of a fully matched stem cell donor, infants with SCID-X1 may receive a transplant from a partial, or "half-matched," donor -- typically their … Continue reading →

Contact Information Available for logged-in reporters only Newswise Seeking a way to stimulate antitumor responses via the immune system, Steven Fiering, PhD, of Norris Cotton Cancer Center at Dartmouth, has identified the precise temperature that results in a distinct body-wide antitumor immune response that resists metastatic disease. Fiering's team published the research in the paper "Local Hyperthermia Treatment of Tumors Induces CD8+ T Cell-Mediated Resistance Against Distal and Secondary Tumors," which appeared in Nanomedicine: Nanotechnology, Biology and Medicine. "Mild hyperthermia treatment of an identified tumor, prior to surgery to remove the tumor, shows excellent promise to strengthen the antitumor response and help stop metastatic disease," explained Fiering. Among the many options for cancer treatment pursued by science, immunotherapy is a contemporary focus. The immune system recognizes and usually eliminates small tumors, but other tumors become clinical problems and are known to block the antitumor tendencies with a natural system for immunosuppression. Recently, scientists have worked to learn how to reverse this tumor-mediated immunosuppression. In addition, phagocytes (key actors in immunosuppression and immunostimulation and that quickly take up nanoparticles) have provided options for new strategies. Fierings's studies were done in mice with a melanoma tumor model, and began with inserting iron … Continue reading →

Parents who gave their children bleach in the belief that it could cure them of autism are being questioned by garda. A number of people who have children with autism have been interviewed by detectives as part of a joint investigation by garda and the Health Products Regulatory Authority (HPRA) into the use of a controversial treatment being promoted in Ireland by an international cult. The substance, known as Miracle Mineral Solution (MMS), is an industrial-strength bleach which its advocates claim acts as a miracle cure for a number of medical conditions, including autism, asthma, Aids, malaria and ebola. Fiona OLeary, an Irish woman who has single-handedly mounted a campaign against a group led by Jim Humble a former Scientologist and self-styled archbishop of the Genesis II Church of Health and Healing said there is need for urgent legislation in Ireland to deter parents from subjecting their children to treatment with MMS. READ NEXT: 7 myths about autism debunked . A dentist and two nurses based in the west of Ireland are among a group of individuals who have also been questioned by garda about the sale of the product. Ms OLeary believes it is unlikely that any parents will … Continue reading →